ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
75.76
-2.49 (-3.18%)
At close: Aug 10, 2026, 4:00 PM EDT
76.76
+1.00 (1.32%)
After-hours: Aug 10, 2026, 7:46 PM EDT
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, ANI Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $108.38. The average 1-year stock price forecast is 43.06% higher than the current stock price, while the lowest is $90 (+18.80%) and the highest is $121 (+59.71%).
Price Target: $108.38 (+43.06%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ANI Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Jefferies No rating | Jefferies | Buy Reiterates $120 | Buy | Reiterates | $120 | +58.39% | Aug 10, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $115 | Buy | Reiterates | $115 | +51.80% | Aug 10, 2026 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $91 → $90 | Hold | Maintains | $91 → $90 | +18.80% | Aug 10, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $124 → $119 | Buy | Reiterates | $124 → $119 | +57.07% | Aug 7, 2026 |
| Barclays | Barclays | Buy Maintains $100 | Buy | Maintains | $100 | +32.00% | Aug 5, 2026 |
Financial Forecast
Revenue This Year
1.11B
from 883.37M
Increased by 25.15%
Revenue Next Year
1.23B
from 1.11B
Increased by 11.57%
EPS This Year
9.29
from 7.89
Increased by 17.76%
EPS Next Year
10.54
from 9.29
Increased by 13.42%
EPS and Forward PE are based on non-GAAP adjusted numbers.